Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.

Reed SD, Newton KM, Garcia RL, Allison KH, Voigt LF, Jordan CD, Epplein M, Swisher E, Upson K, Ehrlich KJ, Weiss NS.

Obstet Gynecol. 2010 Aug;116(2 Pt 1):365-73. doi: 10.1097/AOG.0b013e3181e93330.

3.

Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.

Wheeler DT, Bristow RE, Kurman RJ.

Am J Surg Pathol. 2007 Jul;31(7):988-98.

PMID:
17592264
4.

Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.

Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J.

Cancer. 2006 Feb 15;106(4):812-9.

5.

Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia.

Edris F, Vilos GA, Al-Mubarak A, Ettler HC, Hollett-Caines J, Abu-Rafea B.

J Minim Invasive Gynecol. 2007 Jan-Feb;14(1):68-73.

PMID:
17218233
6.

Progestin therapy of complex endometrial hyperplasia with and without atypia.

Reed SD, Voigt LF, Newton KM, Garcia RH, Allison HK, Epplein M, Jordan D, Swisher E, Weiss NS.

Obstet Gynecol. 2009 Mar;113(3):655-62. doi: 10.1097/AOG.0b013e318198a10a.

7.
8.

Predictors of resolution of complex atypical hyperplasia or grade 1 endometrial adenocarcinoma in premenopausal women treated with progestin therapy.

Penner KR, Dorigo O, Aoyama C, Ostrzega N, Balzer BL, Rao J, Walsh CS, Cass I, Holschneider CH.

Gynecol Oncol. 2012 Mar;124(3):542-8. doi: 10.1016/j.ygyno.2011.11.004.

PMID:
22079678
9.

Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.

Witkiewicz AK, McConnell T, Potoczek M, Emmons RV, Kurman RJ.

Hum Pathol. 2010 Jan;41(1):26-32. doi: 10.1016/j.humpath.2009.06.012.

PMID:
19733383
10.

Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia.

Hahn HS, Chun YK, Kwon YI, Kim TJ, Lee KH, Shim JU, Mok JE, Lim KT.

Eur J Obstet Gynecol Reprod Biol. 2010 May;150(1):80-3. doi: 10.1016/j.ejogrb.2010.02.002.

PMID:
20185225
11.

Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy.

Gunderson CC, Dutta S, Fader AN, Maniar KP, Nasseri-Nik N, Bristow RE, Diaz-Montes TP, Palermo R, Kurman RJ.

Gynecol Oncol. 2014 Jan;132(1):33-7. doi: 10.1016/j.ygyno.2013.11.033.

PMID:
24316307
12.

Preoperative and postoperative correlation of histopathological findings in cases of endometrial hyperplasia.

Gundem G, Sendag F, Kazandi M, Akercan F, Mgoyi L, Terek MC, Zekioglu O.

Eur J Gynaecol Oncol. 2003;24(3-4):330-3.

PMID:
12807251
13.

Risk for advanced-stage endometrial cancer in surgical specimens from patients with complex endometrial hyperplasia with atypia.

Eddib A, Allaf B, Lee J, Yeh J.

Gynecol Obstet Invest. 2012;73(1):38-42. doi: 10.1159/000329326.

PMID:
22056948
14.

[Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].

Cao DY, Yu M, Yang JX, Shen K, Huang HF, Cheng NH, Sun ZY, Deng CY, Yu Q, He FF.

Zhonghua Fu Chan Ke Za Zhi. 2013 Jul;48(7):519-22. Chinese.

PMID:
24284224
15.

[Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].

Yu M, Shen K, Yang JX, Huang HF, Wu M, Pan LY, Lang JH, Lian LJ.

Zhonghua Fu Chan Ke Za Zhi. 2006 Apr;41(4):242-5. Chinese.

PMID:
16759458
17.

Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review.

Gunderson CC, Fader AN, Carson KA, Bristow RE.

Gynecol Oncol. 2012 May;125(2):477-82. doi: 10.1016/j.ygyno.2012.01.003. Review.

PMID:
22245711
18.

Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia.

Shutter J, Wright TC Jr.

Int J Gynecol Pathol. 2005 Oct;24(4):313-8.

PMID:
16175074
19.

LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.

Gallos ID, Krishan P, Shehmar M, Ganesan R, Gupta JK.

Hum Reprod. 2013 Nov;28(11):2966-71. doi: 10.1093/humrep/det320.

20.

Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.

Simpson AN, Feigenberg T, Clarke BA, Gien LT, Ismiil N, Laframboise S, Massey C, Ferguson SE.

Gynecol Oncol. 2014 May;133(2):229-33. doi: 10.1016/j.ygyno.2014.02.020.

PMID:
24561246
Items per page

Supplemental Content

Support Center